Clinical and experimental experience with 39089 BA (trasicor) as an anti-arrhythmic agent.
D000433:1-Propanol / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006168:Guinea Pigs; D006327:Heart Block / Q000188:drug therapy; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008297:Male; D010138:Pacemaker, Artificial; D011437:Propylamines / Q000627:therapeutic use*; D011802:Quinidine / Q000627:therapeutic use; D011817:Rabbits; D013565:Sympatholytics / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D011437:Propylamines; D013565:Sympatholytics; D000433:1-Propanol; D011802:Quinidine; D007545:Isoproterenol